OneMedNet Forms Oncology Data Collaboration with Onco-Innovations and Inka Health to Accelerate Drug Development
Summary
OneMedNet announced a collaboration with Onco-Innovations and its subsidiary Inka Health, granting them access to OneMedNet's iRWD™ platform, powered by Palantir Foundry. This partnership aims to accelerate oncology drug development by leveraging real-world data and AI to support Onco-Innovations' PNKP Inhibitor Technology. For OneMedNet, this agreement serves as a validation of its core technology and platform's capability to identify and characterize specific patient populations, potentially leading to new revenue streams. This positive business development follows recent disclosures of significant revenue growth but also concerns about the company's going concern status and a recent dilutive share offering. Traders will be looking for further details on the financial terms of this collaboration and its potential impact on OneMedNet's financial outlook.
At the time of this announcement, ONMD was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.4M. The 52-week trading range was $0.30 to $4.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.